TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04252300
Drug: Rosuvastatin + BAY1817080
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 5 mg rosuvastatin tablets is administered on Day 8 of Period 2 (total length = 15 days). BAY1817080 is administered as tablets twice daily on Days 1 to 14 of Period 2.
Study: NCT00443898
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle (placebo) applied once daily for 48 weeks
Study: NCT00443898
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle (placebo) applied once daily for 24 weeks
Study: NCT01085617
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01085617
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01085617
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04163835
Drug: 1/2 Normal-dose Wenxin Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 2.5g + Wenxin Granules placebo 7.5g.
Study: NCT04163835
Drug: Twice Normal-dose Wenxin Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 10g.
Study: NCT04163835
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules placebo 10g.
Study: NCT00555646
Drug: PH-10 (rose bengal disodium 0.001%)
Normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment plaque area 1: PH-10 with 544 nm LED light illumination.
Study: NCT00555646
Drug: PH-10 (rose bengal disodium 0.001%)
Normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment plaque area 2: PH-10 with ambient light illumination.
Study: NCT02289716
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
Study: NCT03245762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 IU/day of placebo administered via nasal spray device each morning
Study: NCT03808259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo.
Study: NCT02511106
Drug: AZD9291 80 mg/40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily.
Study: NCT02511106
Drug: Placebo AZD9291 80 mg/40 mg
Normalized name: placebo 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose of Placebo AZD9291 80 mg once daily can be reduced to 40 mg once daily.
Study: NCT01501747
Drug: Caffeine, paracetamol, cephalexin, or ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving the active drug.
Study: NCT00024570
Drug: IL13-PE38QQR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00529555
Drug: minocycline HCl 2.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline HCl 2.1% gel as an adjunct to scaling and root planing. Dosing is by topical delivery into gingival pockets at baseline, 2 weeks, 4 weeks, 3 months and 6 months.
Study: NCT02639078
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time dosing in capsule formulation
Study: NCT02723383
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the placebo will be administered via the nasogastric feeding tube. After extubation, the placebo will be administered either via the nasogastric tube or the oral route.
Study: NCT00005797
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered at a dose of 60 mg/kg on each of two successive days (Days -3 and -2)
Study: NCT01364441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dosed in the same manner as ONO-2952
Study: NCT01373333
Drug: 3,4 DAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended maximum dosage: 20mg four times daily and if needed an additional 20 mg per day for a total of 100 mg per day. Drug must be kept refrigerated at all times.
Study: NCT00004403
Drug: phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04157959
Drug: SHR4640 dose1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet,dose1,QD
Study: NCT02309463
Drug: Endothelin receptor antagonist therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03036150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching dapagliflozin 10 mg or 5 mg
Study: NCT00392886
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00392886
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04263909
Drug: Sublingual Tablet
Normalized name: Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sufentanil SL 30mcg administered sublingually to patients undergoing spine surgery before extubation and during recovery
Study: NCT03617016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo to domperidone tablets orally.
Study: NCT03649997
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered JNJ-61393215-matching placebo in Part 1, 2 and 3 of study as oral suspension.
Study: NCT01974934
Drug: Desvenlafaxine Succinate
Normalized name: Desvenlafaxine Succinate
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01349881
Drug: Eflornithine placebo & sulindac placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years
Study: NCT01349881
Drug: eflornithine & sulindac placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years.
Study: NCT01349881
Drug: Eflornithine placebo & sulindac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
Study: NCT01349881
Drug: Eflornithine plus sulindac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
Study: NCT02668796
Drug: Estradiol Vaginal Tablets 10 mcg (Glenmark)
Normalized name: estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: apply using the given applicator
Study: NCT02668796
Drug: Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)
Approvals — FDA: no, EMA: no, PMDA: no
Description: apply using the given applicator
Study: NCT02668796
Drug: Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)
Normalized name: estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: apply using the given applicator
Study: NCT04175600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets will be administered orally.
Study: NCT04033445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo IV or SC.
Study: NCT02260674
Drug: JNJ-54861911, 10 milligram (mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will self-administer JNJ-54861911, two tablets of 5 mg each for a total of 10 mg, orally, once daily, from Day 1 until Month 6 in treatment group 1.
Study: NCT02260674
Drug: JNJ-54861911, 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6 in treatment group 2.
Study: NCT02260674
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6 in placebo group.
Study: NCT03375697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive matching placebo intravenously.
Study: NCT02048813
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00043407
Drug: CPG 7909
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the phase I portion of the protocol, patients will be included in escalating dose groups: 0.08, 0.12, 0.16, 0.36, 0.54 or 0.81 mg/kg of CPG 7909 Injection. Patients will be treated once weekly subcutaneously for 24 weeks. In the Phase II portion of the trial patients will be treated at the MTD or the highest dose of 0.81 mg/kg identified in the Phase I dose escalation portion of the trial. All patients in Phase I and Phase II will be treated until disease progression or a maximum of 24 weeks.
Study: NCT06801886
Drug: Silymarine supplementation
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of silymarin supplementation daily during the early post-transplant period, (for 30 days) under standard treatment.
Study: NCT04098068
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-3475 (pembrolizumab) 200 mg flat dose every 21 days
Study: NCT00646763
Drug: G-CSF, GM-CSF administered at extremities
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection site Extremities: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a twice daily schedule of G-CSF/GM-CSF until stem cell collection is complete.
Study: NCT03733314
Drug: E6011
Normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE6011
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6011, infusion, intravenously.
Study: NCT03733314
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, infusion, intravenously.
Study: NCT04451187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo of seltorexant OD from Day 1 to Day 8 as a part of Treatment A and C and from Day 2 and Day 7 as a part of Treatment B as per assigned treatment sequence.
Study: NCT00385697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily IV dosing for 14 days, repeated at Week 26
Study: NCT01031186
Drug: GSK356278
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK356278
Study: NCT01031186
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLACEBO
Study: NCT00236483
Drug: tramadol hydrochloride + acetaminophen
Normalized name: acetaminophen / tramadol hydrochloride Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03151993
Drug: Recombinant staphylokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
Study: NCT02864407
Drug: Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The recommended dose for adults is 5 microgram Tiotropium and 5 microgram Olodaterol given as two puffs from the Respimat® inhaler once daily at the same time of the day.
Study: NCT03106935
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine is an orodispersible tablet.For the LT4 treatment group, 50μg LT4 (Merck Serono, Geneva,Switzerland) was administered every morning from the first day of diagnosed as subclinical hypothyroidism and continued up to the day of serum β-HCG measurement.If pregnancy was confirmed, levothyroxine dose need to increase 25-30% and adjusted according to the pregnancy specific reference range ( T1 0.1-2.5mIU/L,T2 0.2-3.0mIU/L, T3 0.3-3.0mIU/L) .
Study: NCT00989313
Drug: Lesion count
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
Study: NCT03871829
Drug: Dara-SC 1800 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dara-SC 1800 mg will be administered by SC injection.
Study: NCT00014222
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 75, 600 and 830 mg/m2
Study: NCT00014222
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2
Study: NCT01998958
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 6 sprays of placebo self-administered as an intranasal formulation for 2 days (Days 1 and 4) or depending on response on Day 8, for 4 days (Days 1,4, 8, 11) during the double-blind phase
Study: NCT04223349
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo in capsule will be administered orally.
Study: NCT00014222
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg/m2
Study: NCT01961921
Drug: ALN-TTR02 (patisiran) administered by intravenous (IV) infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01136798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
Study: NCT02134899
Drug: Calcineurin inhibitors maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment
Study: NCT03100136
Drug: [11C]PF-06809247
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET Tracer
Study: NCT01395914
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02371161
Drug: R-DHAP/R-ICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-DHAP/R-ICE 3 cycles every 21 days:~1. R-DHAP~   * Rituximab 375 mg/m2, e.v. day 1~  * Desamethasone 40 mg days 1-4~  * cis-Platino100 mg/m2, day 2 (if ≥70 years 75 mg/m2)~  * Aracytin 2000 mg/m2, e.v. day 3 (if ≥70 years 1500 mg/m2)~2. R-ICE~   * Rituximab 375 mg/m2, e.v. day 1~  * Etoposide 100 mg/mq, e.v. days 1,2,3 (if ≥70 years 75 mg/mq)~  * Ifosfamide with Mesna equidone 5000 mg/mq, day 2 (if ≥70 years 3750 mg/mq)~  * Carboplatino AUC=5, e.v. (max 800 mg/mq), day 2 (if ≥70 years AUC=4)~Conditioning BEAM or FEAM
Study: NCT02863913
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).
Study: NCT04512898
Drug: Triple therapy for H.pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy of proton pump inhibitors, clarithromycin and metronidazole.
Study: NCT04088864
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is a nitrogen mustard derivative alkylating agent
Study: NCT00053768
Drug: EPOCH regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00053768
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00053768
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01998971
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered in prophylactic doses by mouth in accordance with product labeling and local standards.
Study: NCT01137123
Drug: adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 75mg/m2 +Nedaplatin 75mg/m2,IV drip on day 1 of each 21 day cycle. Number of cycles: till unacceptable toxicity develops and no more than 4 cycles.
Study: NCT01708005
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The comparator is represented by placebo capsules of identical appearance (same size, same color and same smell) that Lecitone®Se-Vitamin D3 capsules.
Study: NCT01211756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU BID for one week, followed by 40 IU BID for 3 weeks.
Study: NCT04445519
Drug: NCX 470 0.065% (initial phase of trial)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCX 470 Ophthalmic Solution, 0.065% (initial phase of trial)
Study: NCT04445519
Drug: NCX 470 0.1% (initial phase of trial)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCX 470 Ophthalmic Solution, 0.1%
Study: NCT04445519
Drug: NCX 470 0.1% (remainder of trial)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCX 470 Ophthalmic Solution, 0.1%
Study: NCT00686088
Drug: PRX302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Determination of the therapeutic activity of different concentrations of PRX302 at increasing volumes and/or number of deposits per gram of prostate.
Study: NCT04343859
Drug: IMMH-010
Approvals — FDA: no, EMA: no, PMDA: no
Description: After tolerance study, 360mg and above IMMH-010 will be administered in Dose expansion study.
Study: NCT04972539
Drug: AJU-A51 Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose AJU-A51(Dapagliflozin/Linagliptin) 10 mg / 5 mg FDC tablet
Study: NCT04972539
Drug: A51R1 Tab. and A51R2 Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose A51R1(Dapagliflozin) 10 mg tablet and A51R2(Linagliptin) 5 mg tablet taken together
Study: NCT03529084
Drug: EFG816
Approvals — FDA: no, EMA: no, PMDA: no
Description: It will be administered orally daily.
Study: NCT00953199
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).
Study: NCT02453516
Drug: epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug indicated to prolong the action of regional anesthesia
Study: NCT00404599
Drug: simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 40mg once a day
Study: NCT04030988
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 patients will receive placebo having the same color, form and packaging as the dexamethasone therapy for 6 months plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments
Study: NCT04328337
Drug: Intralipid, 20% Intravenous Emulsion
Normalized name: Intralipid, 20% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of Intralipid 20%
Study: NCT04328337
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline 30 ml/hr for 12 hours through an IV
Study: NCT02551692
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.~In the NRT group, participants will take a placebo capsule while wearing nicotine patches.
Study: NCT04344756
Drug: Tinzaparin or unfractionated heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin INNOHEP ® 175 IU/kg/24h for 14 days if creatinine clearance Cockcroft ≥ 20mL/min, Otherwise unfractionated heparin (Calciparine®, Héparine Sodique Choay®) subcutaneously or intravenous with an anti-Xa target between 0.5 and 0.7 IU/mL for 14 days
Study: NCT00496834
Drug: Comparator: losartan (+) hydrochlorothiazide (HCTZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
Study: NCT00496834
Drug: Comparator: carvedilol (+) hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
Study: NCT02538679
Drug: US TAP Bupivacaine/Epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
Study: NCT02538679
Drug: Lap TAP Bupivacaine/Epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
Study: NCT00729690
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.
Study: NCT03826875
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed fluoxetine and evaluated for the preventative treatment of depression and health-related quality-of-life